OTCMKTS:JCRRF JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis $4.57 0.00 (0.00%) As of 05/9/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get JCR Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.57▼$4.5750-Day Range$4.57▼$4.5752-Week Range$4.30▼$4.70VolumeN/AAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.Read More… Receive JCRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JCRRF Stock News HeadlinesJCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual MeetingMay 8 at 12:05 PM | businesswire.comNotice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDAMay 7 at 7:11 PM | uk.finance.yahoo.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 10, 2025 | Crypto 101 Media (Ad)JCR Pharmaceuticals Nominates New Audit & Supervisory Board MembersApril 25, 2025 | tipranks.comJCR Pharmaceuticals Begins Construction of New Drug Product PlantFebruary 25, 2025 | tipranks.comJCR Pharmaceuticals' Research Presentations at WORLDSymposiumâ„¢ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage DisordersFebruary 5, 2025 | businesswire.comJCR Pharmaceuticals Showcases Promising Data at WORLDSymposium™ 2025February 5, 2025 | tipranks.comJCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from JefferiesJanuary 29, 2025 | markets.businessinsider.comSee More Headlines JCRRF Stock Analysis - Frequently Asked Questions How have JCRRF shares performed this year? JCR Pharmaceuticals' stock was trading at $4.57 at the start of the year. Since then, JCRRF shares have increased by 0.0% and is now trading at $4.57. View the best growth stocks for 2025 here. How do I buy shares of JCR Pharmaceuticals? Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/10/2025Next Earnings (Estimated)5/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:JCRRF CIKN/A Webwww.jcrpharm.co.jp Phone81 7 9732 8591FaxN/AEmployees934Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:JCRRF) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.